🛡️ Safety first in #INARMOR research!

As part of WP4 (led by #LEITAT), our team completed the in vivo tolerability assessment and established Maximum Tolerated Dose (#MTD) profiles for our therapeutic candidates.
Crucial groundwork before evaluating efficacy in disease models! 🧵👇

New milestone achieved!

The consortium has completed the advanced characterisation of its selected lead compounds for host-directed therapies (HDTs) against antimicrobial resistance.

🔗 inarmor-project.eu

#EUFunded #HaDEA #INARMOR #HorizonEurope #HostDirectedTherapy

Two productive days in Madrid for #INARMOR!

Our 4th Consortium Meeting brought partners together to review progress, align priorities and shape the final phase of the project.

Discussions covered exploitation, stakeholder engagement, diss&comm, as well as project and data management.

#EUFunded

🧵 Day 1 of the 4th #INARMOR Consortium Meeting in Madrid is a wrap!

Today, our 16 Horizon Europe partners came together to review key scientific and development milestones in the fight against antimicrobial resistance (AMR).

#EUFunded #HaDEA

🚨 IN-ARMOR partners meet in Madrid!

On 16–17 September, we hold our 4th Consortium Meeting & 14th MBM, hosted by Servicio Madrileño de Salud.

2 days to review progress, strengthen collaboration and plan the next steps in the fight against #AMR.

#EUFunded #HaDEA #INARMOR #AntimicrobialResistance